Insight

VIPOR for Diffuse Large B-Cell Lymphoma involving the Central Nervous System

cfch.com.sg

Nov 22, 2024, 16:43

VIPOR for Diffuse Large B-Cell Lymphoma involving the Central Nervous System

Ajay Major shared a post on X:

“VIPOR R/R Primary central nervous system lymphoma /non-GC Secondary central nervous system lymphoma

Mark Roschewski, ASH24:

14 patients, most PCNSL
Objective response rate 62 percent / Complete remission 31 percent (ORR 67 percent / CR 22 percent if prior BTKi)
8 donation after circulatory death early, half d/t progression
71 percent diarrhea, 50 percent hypoK Multiple CNS-penetrating agents in VIPOR; should this be followed with consolidation? “

Ajay Major is an Assistant Professor of Medicine at the University of Colorado School of Medicine, specializing in lymphoma and CLL/SLL. He is the Founder and President of Pager Publications, as well as the Founder and Editor-in-Chief of in-House. Additionally, he serves as a Reviewer for the Bellevue Literary Review.

Ajay Major BTKi cancer complete remission hypoK Multiple CNS Mark Roschewski objective response rate OncoDaily Oncology Primary Central Nervous System Lymphoma Secondary central nervous system lymphoma ViPOR

ASCO GI 2025 - Everything You Need To Know About Biggest Gastrointestinal cancer Symposium

Side Effects of Radiotherapy: Risks and What to Know

Isabel Rubio has been elected as the President of the European Cancer Organisation for 2026-2027

Dr. Richard Pazdur's 25 Year WAR on Cancer at the FDA!

China Anti-Cancer Association (CACA) and OncoDaily Announce Strategic Partnership to Advance Global Cancer Care

Special Coverage